Neuromuscular Junction Impairment in Amyotrophic Lateral Sclerosis: Reassessing the Role of Acetylcholinesterase

Maria-Letizia Campanari1,*, María-Salud García-Ayllón2,3,4, Sorana Ciura1, Javier Sáez-Valero2,3 and Edor Kabashi1,*

1 Sorbonne Université, Université Pierre et Marie Curie (UPMC), Université de Paris 06, Unité Mixte 75, Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 1127, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche 7225 Institut du Cerveau et de la Moelle Épineure (ICM), Paris, France, 2 Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, Sant Joan d'Alacant, Spain, 3 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNEDE), Madrid, Spain, 4 Unidad de Investigación, Hospital General Universitario de Elche, FISABIO, Elche, Spain

Amyotrophic Lateral Sclerosis (ALS) is a highly debilitating disease caused by progressive degeneration of motorneurons (MNs). Due to the wide variety of genes and mutations identified in ALS, a highly varied etiology could ultimately converge to produce similar clinical symptoms. A major hypothesis in ALS research is the “distal axonopathy” with pathological changes occurring at the neuromuscular junction (NMJ), at very early stages of the disease, prior to MNs degeneration and onset of clinical symptoms. The NMJ is a highly specialized cholinergic synapse, allowing signaling between muscle and nerve necessary for skeletal muscle function. This nerve-muscle contact is characterized by the clustering of the collagen-tailed form of acetylcholinesterase (ColQ-AChE), together with other components of the extracellular matrix (ECM) and specific key molecules in the NMJ formation. Interestingly, in addition to their cholinergic role AChE is thought to play several “non-classical” roles that do not require catalytic function, most prominent among these is the facilitation of neurite growth, NMJ formation and survival. In all this context, abnormalities of AChE content have been found in plasma of ALS patients, in which AChE changes may reflect the neuromuscular disruption. We review these findings and particularly the evidences of changes of AChE at neuromuscular synapse in the pre-symptomatic stages of ALS.

Keywords: amyotrophic lateral sclerosis (ALS), axonopathy, neuromuscular junction (NMJ), acetylcholinesterase (AChE), collagen tail subunit of asymmetric acetylcholinesterase (ColQ)

NEUROMUSCULAR JUNCTION (NMJ) FORMATION AND STABILIZATION

The vertebrate neuromuscular junction (NMJ) is a “tripartite” synapse, composed by the presynaptic motorneuron (MN), the postsynaptic muscle, and the synapse-associated glial cells (terminal Schwann cells, TSC; Castonguay et al., 2001; Jessen and Mirsky, 2005). Thus, the NMJ is a specialized cholinergic synapse that permits the transmission of action potentials from MNs to muscle. Impairment of NMJ function results in muscle...
weakness or paralysis. In the NMJ, the transmitter acetylcholine (ACh) is released from the MN towards the postsynaptic muscle membrane, folded with crests carrying ACh receptors (AChRs), and troughs with a high density of voltage-gated sodium channels (Flucher and Daniels, 1989; Figure 1A). The muscle fibers are tightly wrapped by a basal lamina containing extracellular matrix (ECM) material (Griffin and Thompson, 2008).

NMJ formation requires interactions between pre- and postsynaptic components during embryonic development. When motor axons reach their final target, muscle fibers already present clusters of AChRs (Yang et al., 2000) which may represent a preferential zone for innervation (Kim and Burden, 2008). Upon contact with muscles, motor axons innervate muscle fibers extensively to generate NMJs (for review Wu et al., 2010). The NMJ specialization is mediated by key molecular mechanisms. Agrin is a glycoprotein synthesized in MNs and released into synaptic clefts. Agrin binds its receptor low-density lipoprotein receptor-related protein 4 (LRP4) to activate the muscle-specific tyrosine kinase receptor (MuSK). Once phosphorylated, MuSK recruits rapsyn, a cytoplasmic scaffolding protein expressed constitutively in myotubes and tightly bonded to AChRs (Lee et al., 2009). Thus, new AChRs are recruited at the NMJ (Sanes and Lichtman, 2001; Figure 1B). The postsynaptic structure is then maintained by a sub-synaptic apparatus provided by the actin cytoskeleton and the dystrophin-glycoprotein complex (DGC), a transmembrane complex of proteins linking the actin cytoskeleton of the muscle to the basal lamina (Bartoli et al., 2001).

At the NMJ, acetylcholinesterase (AChE) rapidly degrades ACh, thus terminating synaptic transmission (Taylor and Radić, 1994). AChE is presented as a protein complex consisting of three catalytic tetramers covalently linked to a non-catalytic subunit: a three-stranded collagen-like tail, called ColQ (Rotundo, 2003; Massoulié and Millard, 2009). ColQ is composed of a central collagenous domain flanked by non-collagenous N and C-terminus domains (Krejci et al., 1997). ColQ interacts with AChE, through the N-terminus (Bon et al., 1997), to perlecan (a heparan sulfate proteoglycan) through the collagen domain (Peng et al., 1999; Arikawa-Hirasawa et al., 2002) and to MuSK through the C-terminus (Cartaud et al., 2004). In turn, perlecan binds to DGC that, as seen before, links the ECM to the cytoskeleton.

**ACETYLCHOLINESTERASE (AChE)**

Vertebrates possess two types of ChEs: AChE and butyrylcholinesterase (BChE). AChE is a crucial enzyme for nerve functions, hydrolyzing ACh in the synaptic cleft, while the function of BChE and its role in the regulation of AChE levels is still under discussion.

AChE exists as three distinct variants coming from alternative exon splicing, each of them with a different C-terminal sequence which determines the possibility to form different oligomeric species (Taylor and Radić, 1994; Massoulié, 2002; Meshorer et al., 2004). The main AChE mRNA transcript in brain and muscle tissues is the AChE-T (tail) variant which subunits constitute the AChE-ColQ complexes. Alternative AChE-H (hydrophobic) and AChE-R (readthrough) variants are less represented. Based on their quaternary structure and on hydrodynamic properties, AChE-T appears under several globular forms: amphiphilic G1, amphiphilic G2, non-amphiphilic G4 and the membrane anchored amphiphilic tetramers bound through the transmembrane subunit Proline Rich Membrane Anchor (PRiMA). The main form at NMJs is asymmetrical, consisting of 1 or 3 tetramers of AChE (A4, A8 or A12) attached to ColQ (for review, see Massoulié et al., 2005). In addition, three more variants exist coming from the 5′-end splicing (Meshorer et al., 2004), called “N-extended” species: N-AChE-T, N-AChE-H and N-AChE-R (Muñoz-Delgado et al., 2010). It results in a complex scenario where multiple forms of the same protein may be regulated by different mechanisms and display different biological roles.

**AChE-ColQ COMPLEX AT THE NMJ**

ColQ deficiency brings to a drastically decreased AChE localization at NMJs (Feng et al., 1999), causing congenital myasthenic syndrome with AChE deficiency (Donger et al., 1998; Ohno et al., 1998, 2013; Schreiner et al., 2007). However, despite its cholinergic role, AChE-ColQ exerts multifunctional roles thanks to the ability of ColQ to binds several partners. Interestingly, AChR clusters are smaller and more densely packed in ColQ-deficient mouse in both muscle cells and in vivo NMJs (Sigoillot et al., 2010). In addition, recent in vitro studies in absence of ColQ revealed the down regulation of several ECM mRNAs (Sigoillot et al., 2016). Laminins, collagens, proteoglycans and other glycoproteins, but also metalloproteases, and other modulators are decreased in ColQ−/− myotubes. Thus, ColQ may modify the postsynaptic differentiation through the regulation of major ECM components.

Also AChE regulates the fate of AChR: in AChE mutant mice the absence of AChE causes a decrease in AChRs density (Adler et al., 2004). Interestingly, BChE can associate with ColQ (Krejci et al., 1997; Feng et al., 1999), but its depletion does not give any phenotype at the NMJ (Li et al., 2006), confirming the specificity of AChE action. Although the catalytic action of AChE in the nervous system has been characterized many years ago, its role in development remains enigmatic. Many evidences, led to the hypothesis that AChE may play non-classical roles, which can be relevant during neural development. In this regard, it has been shown that AChE expression occurs largely before the onset of synaptogenesis, and in the absence of ACh (Layer and Kaulich, 1991; Small et al., 1992, 1995). Moreover, AChE shares sequence homologies with several cell-adhesion proteins, called cholinesterase-like proteins, catalytically inactive but implicated in protein–protein interactions (de la Escaler et al., 1990; Krejci et al., 1991; Grifman et al., 1998; Grisaru et al., 1999). The existence of these proteins provided a convincing reason to assume that AChE itself may be engaged in protein interactions contributing to the formation of cellular junctions by binding other extracellular ligands.
Zebrafish has provided an excellent system to investigate the roles of AChE in vivo due to the absence of BChE gene (Bertrand et al., 2001), while AChE gene is widely expressed throughout development (Hanneman and Westerfield, 1989). A missense mutation in the zebrafish AChE gene, achesb55, was able to abolish ACh hydrolysis. The mutant embryos showed a progressive motility defect and severe reductions in the formation of muscle AChR clusters (Behra et al., 2002). They also had defects in muscle fiber development, with decrease in primary sensory neuron survival and dendritic growth. These defects collectively supported non-classical roles of AChE. Another mutation on AChE gene in zebrafish, the zim (ach), gave rise to a protein, lacking both the catalytic site and the C-terminal neurtogenic domain (Downes and Granato, 2004). This mutation did not cause any motor projections deficit, demonstrating that AChE activity was not required for motor axon growth. However, both mutants did display a decrease in AChR clusters at NMJ. Further experiments on mutant mice presenting deletions of exons 5 and 6 in the AChE gene in the muscles, (mutation which transforms anchored AChE into a soluble enzyme (Camp et al., 2005), with consequent absence of AChE from the NMJ basal lamina (Girard et al., 2006)), were presenting AChR clusters markedly fragmented with a tetanic fade of muscles contraction (Girard et al., 2006). Taken together, these results demonstrated that AChE is dispensable for regulating the stability of neuromuscular synapses. However, the molecular mechanisms behind this regulation remain unknown.

**EARLY SIGN FOR NMJ DESTRUCTION IN AMYOTROPHIC LATERAL SCLEROSIS (ALS)**

Amyotrophic Lateral Sclerosis (ALS) is caused by progressive degeneration of upper and lower MNs with rapid clinical course. Denervated muscles weaken, atrophy and death usually occurs due to respiratory failure in patients within 2–5 years. Despite our knowledge above the genetic causes for this disease, a major question is still opened: Where does MN dysfunction begin? Both dying-forward and dying-back hypothesis have been considered (Kiernan et al., 2011). While the first one proposes an anterograde degeneration of MNs via glutamate excitotoxicity from the cortex, the second raises the possibility that ALS starts distally at the nerve terminal or at the NMJ and progress towards the cell body. In this complicated scenario, the best is to consider back and forward-dying processes as two independent mechanisms that happen simultaneously.
Due to the difficulties in studying human cases, because of the impossibility of obtaining pathological presymptomatic samples, transgenic mice expressing human mutated genes have provided an opportunity to investigate the early stages of the disease. In particular, the human SOD1\textsuperscript{G93A} transgenic mouse is the most commonly used model of ALS (Dupuis and Loeffler, 2009). This animal loses MNs, develops progressive paralysis and dies at 4–5 months of age (Gruzman et al., 2007; Turner and Talbot, 2008). Thus, using this model Fischer et al. (2003) observed denervation at the NMJ by day 47, followed by loss of motor axons between days 47 and 80, and loss of MNs cell bodies after day 80. Interestingly, MNs in hSOD1\textsuperscript{G93A} mice showed diminished retrograde uptake and transport before the manifestation of clinical ALS symptoms (Parkhouse et al., 2008; Bilsland et al., 2010). These results, plus other relevant data discussed by Dadon-Nachum et al. (2011), implied that hSOD1\textsuperscript{G93A} dysfunction is actually a “dying-back” phenomena where distal components are affected early before neuronal degeneration, and symptoms onset.

Also, several results suggested that synapse-specific mechanisms are partly responsible for selective synaptic loss before MNs degeneration. MNs are generally divided into two classes: fast-fatigable (FF) and slow (S) (Heckman and Enoka, 2012). A third kind of MNs exists, the fast-fatigue-resistant (FFR), considered an intermediate phenotype between FF and S MNs, but little is known about its physiology (Stifani, 2014). In hSOD1\textsuperscript{G93A} mouse the FF MNs synapses degenerates while S-MNs synapses remain preserved (Pun et al., 2006). Also the whole muscle and motor unit isometric contractile forces are reduced, 50 days before the onset of clinical symptoms (Hegedus et al., 2007).

Interestingly, the high constitutive expression of hSOD1\textsuperscript{G93A} at the MNs alone is not sufficient to develop early onset of ALS in mouse (Pramatarova et al., 2001; Lino et al., 2002). Notably, the transgenic overexpression of hSOD1\textsuperscript{G93A} at the skeletal muscle, develops progressive muscle atrophy with mitochondrial dysfunction (Dobrowolny et al., 2008); suggesting the role of muscles in disease initiation. This potential role is highlighted by the therapeutic benefit of muscle-targeted treatments. Indeed, the muscle expression of neurotrophic factors delays disease onset, improves locomotor performance, and increases lifespan (Mohajeri et al., 1999; Acsadi et al., 2002; Azzouz et al., 2004; Dobrowolny et al., 2005; Li et al., 2007). Very recently, morphological and pathological changes at hSOD1\textsuperscript{G93A} mouse NMJs architecture have been described as pre-symptomatic hallmarks of the disease (Clark et al., 2016). These observations point to an active role of the muscle fiber and identify the NMJ as a major player in the initiation and progression of ALS.

Further evidences of early dysfunction at the NMJ come from the FUS (FUS\textsubscript{sed in Sarcoma} mutant mice (Sharma et al., 2016). In particular, in the hFUS\textsuperscript{P525L} mouse lines, where the human FUS\textsuperscript{P525L} (found in patients with an aggressive and juvenile-onset form of ALS) mutation is conditionally expressed in MNs, the progressive degeneration is preceded by early (day p20) and selective (FF MNs) motor axons retraction. Also, the NMJs are precociously changed with a drastic reduction of synaptic vesicles and pre- and postsynaptic mitochondria, which appeared dilated and vacuolated as described in mutant hSOD1\textsuperscript{G93A} and hTDP\textsuperscript{A315T} transgenic models of ALS (Magrané et al., 2013).

Very recently, an additional mouse model for ALS has been described carrying the human mutated C9orf72 with the hexanucleotide repeat-expansion at the first intron/promoter (gain-of-function model; O’Rourke et al., 2015). These mice display early nuclear RNA foci and DPR proteins accumulation without showing any sign of neurodegeneration. Also zebrashif partial loss-of-function C9orf72 model have been described leading to motor deficits (Ciura et al., 2013). Probably, C9orf72 models recapitulate the presymptomatic phase of disease which needs of additional genetic factors to manifest the neurodegeneration (Sellier et al., 2016). Probably, it will be an extremely useful model for studying early stages of disease pathogenesis.

**CHOLINERGIC DYSFUNCTION IN ALS**

The cholinergic system deficit emerged as a common pathological hallmark in various neurodegenerative diseases, such as Alzheimer’s disease (AD; Ulrich et al., 1990; Inestrosa et al., 1996; Sáez-Valero et al., 1999), Parkinson’s disease (PD; Bosboom et al., 2003), dementia with Lewy bodies (Förstl et al., 2008), subcortical vascular dementia (Amenta et al., 2002) and Huntington’s disease (Smith et al., 2006). Consequently, AChE attracted considerable attention as a potential therapeutic target (Fernandez et al., 2000; Erkinjuntti et al., 2004; Rampello et al., 2004; Maidment et al., 2005). Indeed, AChE inhibitors partially improve cognitive and functional symptoms, by increasing the synaptic ACh availability. However, little is known about its implication in ALS.

Loss of cholinergic synapses was reported in sporadic ALS patients by studying the expression of vesicular ACh transporter (VACHT), involved in the packaging of ACh inside the synaptic vesicles before release. This protein is localized at the synaptic terminal and considered a marker for cholinergic synapses. Immunohistochemical exams on the spinal MNs revealed a drastic depletion of VACHT immunoreactivity respect to synaptophysin, a marker for MNs synapses integrity. This discrepancy suggested a loss of cholinergic inputs as an early event of ALS neurodegeneration (Nagao et al., 1998). However, the choline acetyltransferase (ChAT) enzyme, responsible for the biosynthesis of ACh, is the most specific indicator for monitoring the cholinergic functional state. Microassay analysis of ChAT activity of single spinal MNs from ALS patients showed lower ChAT activity than in control neurons at an early stage of the disease (Kato, 1989). The loss of activity can be explained by the low ChAT protein contents in ALS preserved MNs (Oda et al., 1995). Recently, to unravel how and when cholinergic function is compromised, the spatiotemporal expression of ChAT from early presymptomatic stages of the hSOD1\textsuperscript{G93A} mouse model, has been analyzed by confocal immunohistochemistry. ChAT content was clearly reduced in MNs soma and cholinergic synaptic terminals very early, before MNs loss and NMJs detachment (Casas et al., 2013). Thus, ChAT reduction may contribute to distal degeneration.
Interestingly, muscle biopsies of ALS patients revealed a reduction in the AChE level (Rasool et al., 1983). Subsequently, analysis of plasma AChE in ALS patients revealed a huge increase in the circulating enzyme (Festoff and Fernandez, 1981). Such a release may reflect a disruption of extracellularly bound AChE at the NMJ. However, the exact source of AChE increase in ALS plasma remains uncertain. In 1983, this hypothesis was confuted by a study were ALS patients plasma samples were compared with neuromuscular disease control groups (which included 2 patients with denervating illnesses). However, no increase of AChE activity was noticed in the second group, suggesting that the increase in AChE activity in ALS plasma was unlikely due to a release of bound enzymes from the NMJ (Rasool et al., 1983). The difficulty to determine human plasma AChE levels without interference by BChE may also explain discrepancies (García-Ayllón et al., 2010, 2012). More information comes from studies in which nerve-muscle integrity was altered, such as denervation or dystrophy, where it has been proved a similar reduction of AChE at the animal NMJ with a subsequent increase in the plasma (Wilson et al., 1973; Fernandez and Inestrosa, 1976). Further data evidence that matrix metalloproteinases (MMP) activity increased in central nervous system as well as in muscles (Schoser and Blottner, 1999) and plasma of ALS patients (Demestre et al., 2005). MMP are a family of Zn$^{2+}$ endopeptidases that are characterized by their ability to digest components of the ECM, such as collagen, proteoglycan, and laminin (Vincenti and Brinckerhoff, 2007) in response to specific changes in neuronal activity or diseases (reviewed by Reinhard et al., 2015). Also, a study on SOD1$^{G93A}$ mice model demonstrated that early treatment with an MMP inhibitor prolongs survival, suggesting a role for MMPs in disease progression, since treatment in the symptom-onset group did not significantly prolonged survival (Lorenzl et al., 2006). We can speculate that such an increase of proteases and collagenases may be related with the in vitro release of AChE found with denervation and denervating illnesses and could be partly the cause of the continuous and progressive interruption of neuromuscular integrity and interrelationships intimately involved in the pathogenesis of ALS.

However, the muscle is not the unique source of AChE in the plasma: MNs have been shown to produce and release AChE (Juliana et al., 1977; Rodríguez-Ithurralde et al., 1997). To complicate the scenario there is the recent discovery of BChE anchored by PRIMA on the surface of TSCs at mouse NMJs (Petrov et al., 2014). In conclusion, the cellular origin of the AChE released in the plasma in ALS and the consequences of its absence at the NMJ is still unclear, since many other functions, not related to the ACh hydrolysis, have been described (Soreq and Seidman, 2001).

**CONCLUSION**

Although the majority of ALS cases are sporadic ALS (sALS) with an unknown etiology, in about 10% of the cases there is a Mendelian inheritance (ALS) where more than 20 genes seems to be implicated (Lattante et al., 2015). Beyond these genes, a huge interested has been put on TARDBP gene, because its protein, TDP-43, is involved in multiple steps of RNA metabolism, including transcription, splicing, or transport of several mRNAs (Lagier-Tourenne et al., 2010; Lattante et al., 2013). Interestingly, ChAT mRNA is a target of TDP-43 (Buratti et al., 2010) and TDP-43 levels and localization in all the spinal MNs are severely affected early in the presymptomatic stage in hSOD1$^{G93A}$ mice, and parallels the development of cholinergic dysfunctions (Casas et al., 2013). In this regard, we can speculate a possible implication for TDP-43 in the direct regulation and dysregulation of AChE or ColQ/PRiMA in ALS. In the same way, would be of great interest to better explore the cholinergic deficit in others, less known, genetical ALS models to give further clues onto the etiopathogenesis of the diseases and to translate data in validation of early biomarkers.

**AUTHOR CONTRIBUTIONS**

Conception and drafting by M-LC. The work was coordinated, revisited and approved by EK, M-SG-A, SC and JS-V.

**FUNDING**

This study was funded by the CIBERNED, Instituto de Salud Carlos III (ISCIII; Cooperative project PI2015/01-4, to JS-V), Spain; Atip/Avenir from Inserm, Career Integration Grant (Marie Curie Actions), Robert Packard Foundation, E-rare ERA-NET program, AFM, ARSLA, France-Alzheimer association and the program “Investissements d’avenir” ANR-10-IAIHU-06 (EK).

**ACKNOWLEDGMENTS**

The authors would like to thank Dr. Pierrick Jego for helping in the revision.

**REFERENCES**

Acsadi, G., Anguelov, R. A., Yang, H., Toth, G., Thomas, R., Jani, A., et al. (2002). Increased survival and function of SOD1 mice after Glial cell- derived neurotrophic factor gene therapy. *Hum. Gene Ther.* 13, 1047–1059. doi: 10.1089/104303402753812458

Adler, M., Manley, H. A., Purcell, A. L., Deshpande, S. S., Hamilton, T. A., Kan, R. K., et al. (2004). Reduced acetylcholine receptor density, morphological remodeling and butyrylcholinesterase activity can sustain muscle function in acetylcholinesterase knockout mice. *Muscle Nerve* 30, 317–327. doi: 10.1002/mus.20099

Amenta, F., Di Tullio, M. A., and Tomassoni, D. (2002). The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies. *Clin. Exp. Hypertens.* 24, 697–713. doi: 10.1081/CEH-120015340

Arikawa-Hirasawa, E., Rossi, S. G., Rotundo, R. L., and Yamada, Y. (2002). Absence of acetylcholinesterase at the neuromuscular junctions of perlecan-null mice. *Nat. Neurosci.* 5, 119–123. doi: 10.1038/nn801

Azzouz, M., Ralph, G. S., Storkebaum, E., Walsmley, L. E., Mitrophanous, K. A., Kingsman, S. M., et al. (2004). VEGF delivery with retrogradely transported lentivirus prolongs survival in a mouse ALS model. *Nature* 429, 413–417. doi: 10.1038/nature02544
Bartoli, M., Ramarao, M. K., and Cohen, J. B. (2001). Interactions of the rapsyn RING-H2 domain with dystroglycan. J. Biol. Chem. 276, 24911–24917. doi: 10.1074/jbc.m003528200

Behra, M., Cousin, X., Bertrand, C., Vonesch, J. L., Biellmann, D., Chatonnnet, A., et al. (2002). Acetylcholinesterase is required for neuronal and muscular development in the zebrafish embryo. Nat. Neurosci. 5, 111–118. doi: 10.1038/nn878

Bertrand, C., Chatonnnet, A., Takke, C., Yan, Y. L., Posthlewat, J., Toutant, J. P., et al. (2001). Zebrafish acetylcholinesterase is encoded by a single gene localized on linkage group 7. Gene structure and polymorphism; molecular forms and expression pattern during development. J. Biol. Chem. 276, 464–474. doi: 10.1074/jbc.m006308200

Bilsland, L. G., Sahai, E., Kelly, G., Golding, M., Greenshmit, L., and Schiavo, G. (2010). Deficits in axonal transport precede ALS symptoms in vivo. Proc. Natl. Acad. Sci. U S A 107, 20523–20528. doi: 10.1073/pnas.1006891107

Bon, S., Coussen, F., and Massoulié, J. (1997). Quaternary associations of acetylcholinesterase II. The polyproline attachment domain of the collagen tail. J. Biol. Chem. 272, 3016–3021. doi: 10.1074/jbc.272.5.3016

Bosboom, J. L. W., Stoffers, D., and Wolters, E. C. (2003). The role of acetylcholine and dopamine in dementia and psychosis in Parkinson’s disease. J. Neural Transm. Suppl. 65, 185–195. doi: 10.1077/978-3-7091-0643-3_11

Buratti, E., De Conti, L., Stuani, C., Romano, M., Baralle, M., and Baralle, F. (2001). Characterization and gene cloning of neurotactin, a Drosophila transmembrane protein related to cholinesterases. J. Cell Biol. 157–158, 79–86. doi: 10.1016/s12031-010-9467-1

Campañari et al. NMJ in Amyotrophic Lateral Sclerosis

Cartaud, A., Strochlic, L., Guerra, M., Blanchard, B., Lambergeon, M., Krejci, E., et al. (2006). MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction. Biol. Interact. 1016/j.jneuroim.2004.09.015

Chan, T. R., Miquet, C., and Tuite, M. J. (1997). Acetylcholinesterase deficiency (Type Ic). Am. J. Hum. Genet. 63, 967–975. doi: 10.1086/302059

Downes, G. B., and Granato, M. (2004). Acetylcholinesterase function is dispensable for sensory neurite growth but is critical for neuromuscular synapse stability. Dev. Biol. 270, 232–245. doi: 10.1016/j.ydbio.2004.09.019-5

Dupuis, L., and Loefler, J. P. (2009). Neuromuscular junction function during amyotrophic lateral sclerosis: insights from transgenic models. Curr. Opin. Pharmacol. 9, 341–346. doi: 10.1016/j.coph.2009.03.007

Erikunjutti, T., Román, G., and Gauthier, S. (2004). Treatment of vascular dementia—evidence from clinical trials with cholinesterase inhibitors. Neuro. Res. 26, 603–605. doi: 10.1179/1016425017631

Feng, G., Krejci, E., Molgo, J., Cunningham, J. M., Massoulié, J., and Sanes, J. R. (1999). Genetic analysis of collagen Q: roles in acetylcholinesterase and butyrylcholinesterase assembly and in synaptic structure and function. J. Cell Biol. 144, 1349–1360. doi: 10.1083/jcb.144.6.1349

Fernandez, H. H., Friedman, J. H., Grace, J., and Beason-Hazen, S. (2000). Donepezil for Huntington’s disease. Mov. Disorder. 15, 173–176. doi: 10.1012/1531-8257(200001)15:1<173::AID-MDS1032>3.0.CO;2-T

Fernandez, H. L., and Inestrosa, N. C. (1976). Role of axoplasmic transport in neurotrophic regulation of muscle end plate acetylcholinesterase. Nature 262, 55–56. doi: 10.1038/262055a0

Festoff, B. W., and Fernandez, H. L. (1981). Plasma and red blood cell acetylcholinesterase in amyotrophic lateral sclerosis. Muscle Nerve 4, 41–47. doi: 10.1002/mus.880040108

Fischer, L. R., Culver, D. G., Tennant, P., Davis, A. A., Wang, M., Castellano-Sanchez, A., et al. (2003). Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol. 185, 232–240. doi: 10.1016/j.expneurol.2003.10.004

Flucher, B. E., and Daniels, M. P. (1989). Distribution of Na+ channels and ankyrin in neuromuscular junctions is complementary to that of acetylcholine receptors and the 43 kD protein. Neuron 3, 163–175. doi: 10.1016/0896-6273(89)90029-9

Forsl, H., Grat, S., Hahn, U., Schwarz, J., and Jarnig, M. (2008). Dementia with Lewy bodies and reduced dopamine transporter binding indicates significant acetylcholine deficiency. Disch. Med. Wochenschr. 133, S11–S14. doi: 10.1055/s-2008-1075880

García-Ayllón, M. S., Millán, C., Serra-Basante, C., Bataller, R., and Sáez-Valero, J. (2012). Readthrough acetylcholinesterase is increased in human liver cirrhosis. PlasLoe One 7:e44598. doi: 10.1371/journal.pone.0044598

García-Ayllón, M. S., Riba-Llena, I., Serra-Basante, C., Alom, J., Boopathy, S., and Sáez-Valero, J. (2010). Altered levels of acetylcholinesterase in Alzheimer plasma. PlasLoe One 5:e8701. doi: 10.1371/journal.pone.0008870

Girard, E., Bernard, V., Camp, S., Taylor, P., Krejci, E., and Molgo, J. (2006). Remodeling of the neuromuscular junction in mice with deleted exons 5 and 6 of acetylcholinesterase. J. Mol. Neurosci. 30, 99–100. doi: 10.1385/jmn:30:1<99::AID-JMOE1016>.3.0.CO;2-T

Girgenti, J. W., and Thompson, W. J. (2008). Biology and pathology of non-mydriating Schwann cells. Glia 56, 1518–1531. doi: 10.1002/glia.20778

Girman, M., Galyam, N., Seidman, S., and Soreq, H. (1998). Functional redundancy of acetylcholinesterase and neurologin in mammalian neuotogenesis. Proc. Natl. Acad. Sci. U S A 95, 13935–13940. doi: 10.1073/pnas.95.23.13935

Gisraru, D., Sternfeld, M., Eldor, A., Glick, D., and Soreq, H. (1999). Structural roles of acetylcholinesterase variants in biology and pathology. Eur. J. Biochem. 264, 672–686. doi: 10.1111/j.1432-1327.1999.00693.x

Gruzman, A., Wood, W. L., Alpert, E., Prasad, M. D., Miller, R. G., Rothstein, J. D., et al. (2007). Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U S A 104, 12524–12529. doi: 10.1073/pnas.070544104

Hannemann, E., and Westerfield, M. (1989). Early expression of acetylcholinesterase activity in functionally distinct neurons of the zebrafish. J. Comp. Neurol. 284, 350–361. doi: 10.1002/cne.920840303

Heckman, C. J., and Enoka, R. M. (2012). Motor unit. Compr. Physiol. 2, 2629–2682. doi: 10.1002/cphy.c100087

Hegedus, J., Putman, C. T., and Gordon, T. (2007). Time course of preferential motor neuron loss in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 28, 154–164. doi: 10.1016/j.nbd.2007.07.003

Inestrosa, N. C., Alvarez, A., Pérez, C. A., Moreno, R. D., Vicente, M., Linke, C., et al. (1996). Acetylcholinesterase accelerates assembly of amyloid-beta...
peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. *Neuron* 16, 881–891. doi: 10.1016/s0896-6273(00)80108-7

Jessen, K. R., and Mirsky, R. (2005). The origin and development of glial cells in peripheral nerves. *Nat. Rev. Neurosci.* 6, 671–682. doi: 10.1038/nrn1746

Juliana, T. H., Chuy, J. Y., and Max, S. R. (1977). Release of acetylcholinesterase by cultured spinal cord cells. *J. Neurobiol.* 8, 469–476. doi: 10.1002/neu.480080507

Kato, T. (1989). Choline acetyltransferase activities in single spinal motor neurons from patients with amyotrophic lateral sclerosis. *J. Neurochem.* 52, 636–640. doi: 10.1111/j.1471-4159.1989.tb09167.x

Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., et al. (2011). Amyotrophic lateral sclerosis. *Lancet* 377, 942–955. doi: 10.1016/S0140-6736(10)61556-7

Kim, N., and Burden, S. J. (2008). MuSK controls where motor axons grow and form synapses. *Nat. Neurosci.* 11, 19–27. doi: 10.1038/nm2026

Krejci, E., Chatonnet, A., Vincens, P., and Massoulié, J. (1991). Cholinesterase-like domains in enzymes and structural proteins: functional and evolutionary relationships and identification of a catalytically essential aspartic acid. *Proc. Natl. Acad. Sci. U S A* 88, 6667–6671. doi: 10.1073/pnas.88.15.6647

Krejci, E., Thomine, S., Boschetti, N., Legacy, C., Sketel, J., and Massoulié, J. (1997). The mammalian gene of acetylcholinesterase-associated collagen. *J. Biol. Chem.* 272, 22840–22847. doi: 10.1074/jbc.272.36.22840

Lagier-Tourenne, C., Polymenidou, M., and Cleveland, D. W. (2010). TDP-43 and mitochondrial transport and morphology are common pathological features in transgenic ALS mice. *Neuron* 20, 166–171. doi: 10.1016/j.expneurol.2009.09.028

Lamprou, K. A., Girard, E., Nikitashina, A. D., Colasante, C., Bernard, V., Ohno, K., Ito, M., Kawakami, Y., Krejci, E., and Engel, A. G. (1998). Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymptomatic enzyme. *Proc. Natl. Acad. Sci. U S A* 95, 9654–9659. doi: 10.1073/pnas.95.15.9654

Ohno, K., Ito, M., Kawakami, Y., Krejci, E., and Engel, A. G. (2013). Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis. *Chem. Biol. Interact.* 203, 335–340. doi: 10.1016/j.cbii.2012.08.020

O’Rourke, J. G., Bogdanik, L., Muhammad, A. K., Gendron, T. F., Kim, K. J., Austin, A., et al. (2015). C9orf72 BAC transgenic mice display typical pathological features of ALS/FTD. *Neuron* 88, 892–901. doi: 10.1016/j.neuron.2015.10.027

Parkhouse, W. S., Cunningham, L., McFea, L., Miller, J. M., Whitney, D., Pelech, S. L., et al. (2008). Neuromuscular dysfunction in the mutant superoxide dismutase mouse model of amyotrophic lateral sclerosis. *Amyotroph. Lateral Scler.* 9, 24–34. doi: 10.1080/17482900701725646

Peng, H. B., Xie, H., Rossi, S. G., and Rotundo, R. L. (1999). Acetylcholinesterase clustering at the neuromuscular junction involves perlecan and dystroglycan. *J. Cell Biol.* 145, 911–921. doi: 10.1083/jcb.145.4.911

Petrikov, K. A., Girard, E., Nikitashina, A. D., Colasante, C., Bernard, V., Nuruldin, L., et al. (2014). Cellular/molecular schwann cells sense and control acetylcholine spillover at the neuromuscular junction by α7 nicotinic receptors and butyrylcholinesterase. *J. Neurosci.* 34, 11870–11883. doi: 10.1523/JNEUROSCI.0329-14.2014

Pramatarova, A., Laganiere, J., Roussel, J., Brisebois, K., and Rouleau, G. A. (2001). Neuro-exon-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. *J. Neurosci.* 21, 3369–3374.

Pun, S., Santos, A. F., Saxena, S., Xu, L., and Caroni, P. (2006). Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. *Nat. Neurosci.* 9, 408–419. doi: 10.1038/nneuro.2006.1163

Rampello, L., Cerasa, S., Alvano, A., Buttì, V., Raffaele, R., Vecchio, I., et al. (2004). Dementia with Lewy bodies: a review. *Arch. Gerontol. Geriatr.* 39, 1–14. doi: 10.1016/j.archger.2003.11.003

Rasool, C. G., Bradley, W. G., Connolly, B., and Barauh, J. K. (1983). Acetylcholinesterase and ATPases in motor neuron disease. *Muscle Nerve* 6, 430–435. doi: 10.1002/mus.880060606

Reinhard, S. M., Razak, K., and Ethell, I. M. (2015). A delicate balance: role of MMP-9 in brain development and pathophysiology of neurodevelopmental disorders. *Front. Cell. Neurosci.* 9:280. doi: 10.3389/fncel.2015.00280

Rodrigo-Thurrauld, D., Oliveira, S., Vincent, O., and Maruri, A. (1997). In vivo and in vitro studies of glycine- and glutamate-evoked acetylcholinesterase release from spinal motor neurons: implications for amyotrophic lateral sclerosis/motor neuron disease pathogenesis. *J. Neurosci. Sci.* 152, 534–561. doi: 10.1016/S0022-5191(97)00245-1

Rotundo, R. L. (2003). Expression and localization of acetylcholinesterase at the neuromuscular junction. *J. Neurocytol.* 32, 743–766. doi: 10.1023/b:neur.000002631.58197.d4

Saez-Valero, J., Sherna, G., McLean, C. A., and Small, D. H. (1999). Molecular isoform distribution and glycosylation of acetylcholinesterase are altered...
in brain and cerebrospinal fluid of patients with Alzheimer’s disease. *J. Neurochem.* 72, 1600–1608. doi: 10.1046/j.1471-4159.1999.721600.x

Sanes, J. R., and Lichtman, J. W. (2001). Induction, assembly, maturation and maintenance of a postsynaptic apparatus. *Nat. Rev. Neurosci.* 2, 791–805. doi: 10.1038/35097557

Schoser, B. G., and Blottner, D. (1999). Matrix metalloproteinases MMP-2, MMP-7 and MMP-9 in denervated human muscle. *Neuroreport* 10, 2795–2797. doi: 10.1097/00001756-199909090-00018

Schreiner, F., Hoppenz, M., Klaeren, R., Reimann, J., and Woelfle, J. (2007). Novel COLQ mutation 950delC in synaptic congenital myasthenic syndrome with acetylcholinesterase deficiency. *Neuromuscul. Disord.* 17, 262–265. doi: 10.1016/j.nmd.2006.11.010

Sellier, C., Campanari, M. L., Julie Corbier, C., Gaucherot, A., Kolb-Cheynel, I., Oulad-Abdelghani, M., et al. (2016). Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death. *EMBO J.* 35, 1276–1297. doi: 10.15252/embr.201593350

Sharma, A., Lyashchenko, A. K., Lu, L., Nasrabady, S. E., Elmaleh, M., Mendelsohn, M., et al. (2016). ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. *Nat. Commun.* 7:10465. doi: 10.1038/ncomms10465

Sigouillot, S. M., Bourgeois, F., Karmouch, J., Molgó, J., Dobbertin, A., Chevalier, C., et al. (2016). Neuromuscular junction immaturity and muscle atrophy are hallmarks of the ColQ-deficient mouse, a model of congenital myasthenic syndrome with acetylcholinesterase deficiency. *FASEB J.* 30, 2382–2399. doi: 10.1096/fj.201500162

Sigouillot, S. M., Bourgeois, F., Lambergeon, M., Strochlic, L., and Legay, C. (2010). ColQ controls postsynaptic differentiation at the neuromuscular junction. *J. Neurosci.* 30, 13–23. doi: 10.1523/JNEUROSCI.4374-09.2010

Small, D. H., Nurcombe, V., Moir, R., Michaelson, S., Monard, D., Beyreuther, K., et al. (1992). Association and release of the amyloid protein precursor of Alzheimer’s disease from chick brain extracellular matrix. *J. Neurosci.* 12, 4143–4150.

Small, D. H., Reed, G., Whitefield, B., and Nurcombe, V. (1995). Cholinergic regulation of neurite outgrowth from isolated chick sympathetic neurons in culture. *J. Neurosci.* 15, 144–151.

Smith, R., Chung, H., Rundquist, S., Maat-Schieman, M. L., Colgan, L., Englund, E., et al. (2006). Cholinergic neuronal defect without cell loss in Huntington’s disease. *Hum. Mol. Genet.* 15, 3119–3131. doi: 10.1093/hmg/ddl252

Soreq, H., and Seidman, S. (2001). Acetylcholinesterase–new roles for an old actor. *Nat. Rev. Neurosci.* 2, 294–302. doi: 10.1038/35067589

Stifani, N. (2014). Motor neurons and the generation of spinal motor neuron death. *Front. Cell. Neurosci.* 8:293. doi: 10.3389/fncel.2014.00293

Taylor, P., and Radić, Z. (1994). The cholinesterases: from genes to proteins. *Annu. Rev. Pharmacol. Toxicol.* 34, 281–320. doi: 10.1146/annurev.toxinc.34.1.281

Turner, B. J., and Talbot, K. (2008). Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. *Prog. Neurobiol.* 85, 94–134. doi: 10.1016/j.pneurobio.2008.01.001

Ulrich, J., Meier-Ruge, W., Probst, A., Meier, E., and Ipsen, S. (1990). Senile plaques staining for acetylcholinesterase and A4 protein: a comparative study in the hippocampus and entorhinal cortex. *Acta Neuropathol.* 80, 624–628. doi: 10.1007/bf00307630

Vincenti, M. P., and Brinckerhoff, C. E. (2007). Signal transduction and cell-type specific regulation of matrix metalloproteinase gene expression: can MMPs be good for you? *J. Cell. Physiol.* 213, 355–364. doi: 10.1002/jcp.21208

Wilson, B. W., Linkhart, T. A., Walker, C. R., and Nieberg, P. S. (1973). Tissue acetylcholinesterase in plasma of chick embryos and dystrophic chickens. *J. Neurosci.* 18, 333–350. doi: 10.1016/0022-510x(73)90082-8

Wu, H., Xiong, W. C., and Mei, L. (2010). To build a synapse: signaling pathways in neuromuscular junction assembly. *Development* 137, 1017–1033. doi: 10.1242/dev.038711

Yang, X., Li, W., Prescott, E. D., Burden, S. J., and Wang, J. C. (2000). DNA topoisomerase II beta and neural development. *Science* 287, 131–134. doi: 10.1126/science.287.5450.131

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2016 Campanari, García-Ayllón, Ciura, Sáez-Valero and Kabashi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*